导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -6.59% | 52/147 |
| 近一周 | -2.53% | 25/153 |
| 近一月 | -1.67% | 49/153 |
| 近一季 | -0.85% | 37/153 |
| 近半年 | -3.89% | 50/149 |
| 近一年 | -10.31% | 29/144 |
| 近两年 | 35.59% | 52/119 |
| 近三年 | 31.95% | 26/89 |
| 成立以来 | 31.62% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.13% 131/360 |
-8.09% 250/366 |
- - |
- - |
| 2025 | 24.86% 73/358 |
14.54% 101/340 |
3.63% 203/348 |
10.98% 138/354 |
-5.21% 213/358 |
| 2024 | 21.82% 87/329 |
-2.83% 199/280 |
8.71% 37/310 |
18.39% 92/318 |
-2.60% 187/329 |
| 2023 | -10.79% 161/275 |
0.72% 144/205 |
-1.35% 128/230 |
-7.34% 200/262 |
-3.10% 212/276 |
| 2022 | -5.55% 27/201 |
-5.92% 42/153 |
5.32% 55/164 |
-14.82% 98/189 |
11.90% 85/202 |
| 2021 | -14.88% 76/150 |
3.91% 94/312 |
0.35% 229/328 |
-13.00% 242/358 |
-6.16% 82/151 |
| 2020 | -10.24% 71/103 |
-13.78% 179/280 |
3.84% 241/295 |
-5.82% 268/299 |
6.45% 185/305 |
| 2019 | 11.71% 64/88 |
9.26% 140/258 |
1.66% 125/268 |
-5.47% 226/253 |
6.39% 137/266 |
| 2018 | -8.37% 40/79 |
- - |
- - |
- - |
-6.87% 80/241 |
| 2017 | 27.30% 15/69 |
- - |
- - |
- - |
- - |
| 2016 | 7.64% 23/59 |
- - |
- - |
- - |
- - |
| 2015 | -7.15% 32/49 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 广发中证香港创新药ETF(QDII) | 1.2744 | 27.49% |
| 广发道琼斯石油指数人民币A | 3.2498 | 26.68% |
| 广发道琼斯石油指数人民币C | 3.1927 | 26.58% |
| 广发道琼斯石油指数(QDII-LOF)人民币E | 3.2003 | 26.55% |
| 广发中证香港创新药ETF发起式联接(QDII)C | 1.3286 | 26.01% |
| 富国标普石油天然气勘探及生产精选行业ETF(QDII) | 1.4105 | 25.68% |
| 汇添富恒生生物科技ETF(QDII) | 1.1055 | 25.31% |
| 南方恒生生物科技ETF(QDII) | 1.1206 | 25.14% |
| 华宝标普油气上游股票美元A | 0.1538 | 24.94% |
| 广发中证香港创新药ETF发起式联接(QDII)A | 1.3401 | 24.24% |
| 汇添富恒生指数(QDII-LOF)A VS. 建信富时100指数(QDII)人民币A(539003) |